# LUCERNA (NCT06901531)

> A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06901531
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions: zolbetuximab; Pembrolizumab; Capecitabine; Oxaliplatin; Folinic acid (leucovorin or local equivalent); 5-fluorouracil (5-FU); Placebo
- Enrollment: 500
- Primary outcome: Overall Survival (OS)

## Commentary we found

- YouTube: 13
- X threads: 11
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=lucerna-nct06901531

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06901531", "email": "<work email>"}; the inbox owner confirms by the emailed link.